文献速递临床试验与 GCP

不同剂量富血小板血浆治疗中度腕管综合征的疗效:中国广州前瞻性随机对照试验研究方案

Efficacy of different doses of platelet-rich plasma for moderate carpal tunnel syndrome: study protocol for a prospective, randomized, controlled trial in Guangzhou, China.
PubMed 文献 · Trials · 2026-02-25

本研究为在中国广州开展的前瞻性、双盲、随机、平行组、优效性对照试验,计划招募60例经肌电图确诊的中度腕管综合征成人患者,按1:1随机接受超声引导下3 mL或5 mL富血小板血浆注射,基线及2周时各注射一次,主要结局为基线至6个月麻木视觉模拟评分变化。

要点

  • 研究比较3 mL与5 mL富血小板血浆注射治疗中度腕管综合征的疗效差异。
  • 主要结局为基线至6个月麻木视觉模拟评分的变化。
  • 试验在中国临床试验注册中心注册(ChiCTR2400094746),为回顾性注册。

核心结论

  • 该研究方案旨在评估不同剂量富血小板血浆注射治疗中度腕管综合征的疗效,为注射治疗的最佳剂量提供建议并为临床应用提供指导。

研究设计与样本

  • 前瞻性、双盲、随机、平行组、优效性对照试验,在中国广州南方医科大学第三附属医院开展。
  • 计划招募60例年龄20-80岁、经肌电图确诊的中度腕管综合征成人患者,麻木视觉模拟评分≥40 mm(100 mm量表)。
  • 参与者按1:1比例随机接受超声引导下3 mL或5 mL富血小板血浆注射,基线及2周时各注射一次。
  • 主要结局为基线至6个月麻木视觉模拟评分的变化;次要结局包括超声参数、波士顿腕管综合征问卷症状严重程度量表与功能状态量表、神经电生理指标;安全性结局包括所有不良事件及注射相关并发症。
  • 数据分析采用意向性治疗和符合方案集两种方法,使用IBM SPSS统计软件。

局限性

  • 试验为回顾性注册,注册时间为2024年12月26日,首例参与者入组时间为2024年9月30日。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carpal tunnel syndrome (CTS) is the most prevalent peripheral nerve disorder, with a reported lifetime prevalence of approximately 8% in the general population, and higher rates observed in females than in males (approximately 10% vs. 5.8%), based on global epidemiological estimates. Recently, Platelet-rich plasma (PRP) injections have attracted increasing attention as an innovative treatment, proving more effective than corticosteroids and dextrose. However, the optimal PRP therapeutic dosage remains unclear. This study aims to determine if a 5 mL (vs. 3 mL) platelet-rich plasma injection around the median nerve more effectively relieves symptoms in moderate carpal tunnel syndrome patients. METHODS: This prospective, double-blind, randomized, parallel-group, superiority-controlled trial will be conducted at the Third Affiliated Hospital of Southern Medical University (a tertiary academic hospital) in Guangzhou, China. Trained rehabilitation physicians in the outpatient department of Rehabilitation Medicine, will recruit 60 adults with moderate CTS and obtain informed consent. Participants will be randomly assigned (a 1:1 ratio) to receive either 3 mL or 5 mL PRP injection under ultrasound guidance at baseline and at 2 weeks. Eligible participants are adults aged 20-80 years with electromyography (EMG)-confirmed moderate CTS, a numbness score ≥ 40 mm on a 100-mm Visual Analogue Scale (VAS). Additionally, all injections will be performed by physicians who have completed advanced training in ultrasound-guided peripheral nerve injection procedures and all participants will receive standardized health education from licensed physiotherapists with at least three years of specialized experience. The primary outcome is the change in the VAS score of numbness from baseline to 6 months. Secondary outcomes include changes in ultrasound parameters (cross-sectional area (CSA), blood flow of median nerve (MNBF), and swollen rate of median nerve (MNSR)), Boston Carpal Tunnel Syndrome Questionnaire-Symptom Severity Scale (BCTQ-SSS), Boston Carpal Tunnel Syndrome Questionnaire-Functional Status Scale (BCTQ-FSS), electrophysiological measures (sensory nerve conduction velocity (SNCV), distal motor latency (DML)). Safety outcomes include all adverse events (AEs) and injection-related complications recorded throughout follow-up. Data will be analyzed by using intention-to-treat and per-protocol approaches. All analyses will be performed using IBM SPSS Statistics software. DISCUSSION: The results of this study will evaluate the efficacy of different doses of PRP injection in the treatment of moderate CTS, thereby providing suggestions on the optimal dose for injection therapy and offering guidance for clinical application. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2400094746). Retrospectively registered on 26 December 2024. https://www.chictr.org.cn/showproj.html?proj=252770 . The first participant was enrolled on 30 September 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Li Y, Lu Y, Wei Z, et al. Efficacy of different doses of platelet-rich plasma for moderate carpal tunnel syndrome: study protocol for a prospective, randomized, controlled trial in Guangzhou, China. Trials. 2026. PMID: 41742293. doi:10.1186/s13063-026-09538-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。